Adaptyv closed a $40 million Series A led by Highland Europe. Y Combinator, ACE Ventures, and byFounders returned. Valuation was not disclosed. The company says throughput grew more than 5x and names Chai Discovery, Boltz, Roche, and Novo Nordisk as customers.
AusperBio closed a $120 million Series C on August 27, 2026. An unnamed strategic investor led. RA Capital joined. The company cites $360 million raised since 2024. Valuation was not disclosed. AHB-137 is in Phase 3 in China and remains investigational.
Gap-fill investment explainers: Palona $20M, HubX up to $75M @ $1.2B pre, Yardstik $30M, Capital F $17M fund, Atorie $9.5M deep dive, and Keenable $26M deep dive — who uses the products and why these capital sources fit.
Sunday August 30 added almost no new company-disclosed mega-tape. The gap-fill is AusperBio’s $120M Series C (unnamed lead), Warpify and fileAI checks with no published dollars, YZi Labs’ $500K De¹ residency check, and YC’s apply page rolling from Fall 2026 to Winter 2027.
Owner announced a $240 million Series D on August 28, 2026, at $2.3 billion, led by Goldman Sachs Alternatives. The company says it has surpassed $100 million ARR. Meritech, Redpoint, Headline, and Jack Altman participated. No Goldman or Meritech fund pages here.
OpenAI said on August 28, 2026 that it will wind down the contract that supplies its models to Cursor after the SpaceX close. Proposed shutoff: November 12, 2026. The $60 billion acquisition price remains press. Cursor’s CEO said OpenAI is about 5% of user traffic.
